"FDA Gives Green Light to Eli Lilly's Zepbound: A Breakthrough Weight Loss Medication"
The FDA has approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or overweight and at least one weight-related condition. Zepbound activates receptors in the intestine to reduce appetite and food intake. It is administered once weekly via injection and has been shown to significantly reduce body weight in clinical trials. However, it can cause side effects such as nausea and diarrhea. Zepbound should not be used in patients with a history of medullary thyroid cancer or severe gastrointestinal disease. It should also not be used in combination with certain medications.